
Welcome to Episode #7 of NAF This Week!
Join National Ataxia Foundation CEO Andrew Rosen for a quick look at what’s happening across NAF and the Ataxia community — from research and advocacy to programs, events, and more.
In this episode:
This week, Andrew discusses the latest developments in Biohaven's resubmitted FDA application for troriluzole, an investigational treatment for Spinocerebellar Ataxia (SCA). He looks back at the drug's regulatory journey, explains the steps that have led to this point, and shares what may come next for the Ataxia community.
Links & Resources Mentioned:
🔗 Biohaven SEC Filing: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000083/bhvn-20261022.htm
🔗 What is an Investigational New Drug (IND) application?: https://www.ataxia.org/what-is-an-investigational-new-drug-ind-application/
🔗 All About PDUFA Dates: https://www.ataxia.org/all-about-pdufa-dates/
Stay Connected with NAF: Visit www.ataxia.org to learn more about Ataxia, find resources and support, get involved, and follow the latest progress in Ataxia research.
More episodes from "NAF This Week"



Don't miss an episode of “NAF This Week” and subscribe to it in the GetPodcast app.







